AOD-9604

AOD-9604 is the cleanest single-case study in the corpus of a peptide whose preclinical story made it to Phase IIb and whose Phase IIb made it not to a Phase III but to a press release announcing the end of obesity development. The honest 2026 read of the molecule must lead with that fact. Metabolic Pharmaceuticals Ltd. (Melbourne) ran six human trials of AOD-9604 between 2001 and 2006, totalling roughly 900 participants, and concluded the obesity program with a 24-week placebo-controlled Phase IIb (METAOD006, ACTRN12605000067673) that did not differentiate any active oral dose arm from placebo on the primary weight-loss endpoint at 12 weeks. The program effectively ended on that result. Metabolic Pharmaceuticals subsequently rebranded toward a cartilage / osteoarthritis indication and out-licensed the asset; the obesity story did not progress to a Phase III in any jurisdiction. The Phase IIb results were eventually published in a 2015 narrative description by the Stier / Vos / Kenley group (Stier et al., J Endocrinol Metab 2013, 3(1-2):7-15) as part of the integrated safety summary, but no peer-reviewed efficacy paper from the failed 24-week trial has been published in a high-impact obesity journal; the public record consists of company disclosures, ASX press releases, the integrated safety publication, and the ANZCTR registry record.

The earlier Phase IIa signal that fed the IIb investment is worth specifying because the marketing literature in 2026 still cites it. Herd et al. 2005, presented at the North American Association for the Study of Obesity, reported that the 1 mg oral dose arm in a 12-week 300-patient study (METAOD005) produced ~2.8 kg weight loss versus ~0.8 kg on placebo — a separation that, on a 12-week timescale, encouraged the larger and longer METAOD006 design. The longer trial then did not reproduce the signal, which is the modal outcome when a small Phase IIa effect dilutes through tighter blinding, broader recruitment, and a longer endpoint window. The compounding-pharmacy and gray-market narrative around AOD-9604 in 2026 still anchors to the IIa-positive 1 mg result and the rodent lipolysis case, while skipping the IIb-negative outcome that ended the obesity development program — a sequence that the /critic/aod-9604-fat-loss-claims response disambiguates in detail.

A secondary indication track opened in the 2010s around intra-articular cartilage support. Kwon and Park 2015 studied weekly intra-articular AOD-9604 injections (with and without hyaluronic acid) in a 32-rabbit collagenase-induced knee osteoarthritis model and reported that combined AOD-9604 + HA reduced histological cartilage degeneration more than HA alone (Kwon & Park, Ann Clin Lab Sci 2015, 45(4):426-32). This is a rabbit-model preclinical result; no controlled human OA trial of AOD-9604 has been published. The intra-articular OA mention is included here because it is the only post-obesity-program human-adjacent indication discussed in the literature, not because it represents validated clinical evidence.

The regulatory status of AOD-9604 in 2026 is split across two artifacts that the marketing literature frequently conflates. First, the originator company (later trading under the Calzada / Phosphagenics / Lateral Pharma corporate lineage) issued a Generally Recognized As Safe self-determination in 2014 for AOD-9604 as a food and supplement ingredient, citing the integrated safety dataset summarized by Stier et al. 2013 and the 2014 metabolism characterization by Moré et al. in the same journal. GRAS is a safety determination for food-additive use; it does not assert efficacy for any therapeutic claim, and the FDA's public GRAS notice inventory does not list a corresponding agency "no questions" letter under the AOD-9604 name as of 2026 — the determination is a self-affirmation rather than an agency-reviewed GRN. Second, Australia's Therapeutic Goods Administration has at various points listed AOD-9604-containing products as "listed medicines" under the complementary-medicine pathway, which is the TGA's lower-risk listing for products making restricted claims; this is regulatory permission to market in a specific channel, not a clinical-evidence endorsement. Neither artifact contradicts the Phase IIb result and neither should be read as filling the efficacy gap the failed trial left.

The position in the corpus is therefore distinct from every other metabolic peptide on the site. Semaglutide and Tirzepatide anchor the modern fat-loss conversation on large Phase III RCTs with weight reductions in the 15–22% range. Tesamorelin anchors the visceral-fat-specific GH-axis case on a 412-patient FDA-approval-grade NEJM trial. AOD-9604 sits below all three as a peptide whose pivotal-trial efficacy data point against the clinical claim it is marketed for. The fat-loss decision guide treats AOD-9604 as a non-recommendation specifically on those grounds: there is no controlled-trial evidence that the peptide produces clinically meaningful weight loss at any human dose tested, and a peptide with a failed pivotal trial is structurally distinct from a peptide with no pivotal trial at all. The "no GH receptor binding, no IGF-1 elevation" framing — the marketing line in 2026 — is mechanistically true and clinically empty: a mechanism with no efficacy is just a mechanism. The /critic/aod-9604-fat-loss-claims response walks the specific marketing-versus-evidence reconstruction.

A final note on routes. The original Metabolic Pharmaceuticals development program tested AOD-9604 primarily orally — the engineering bet was that the small constrained peptide would clear the intestinal-absorption hurdle that ends most peptide drug-development programs. The failed METAOD006 was an oral-tablet trial. The compounded-pharmacy and research-channel use of AOD-9604 in 2026 is almost exclusively subcutaneous, on the implicit logic that injection bypasses any absorption problem the oral arms may have had. There is no published human controlled-trial evidence that the subcutaneous route produces weight loss either; the substitution of the injectable route for the failed oral route is a recreational-channel inference, not an evidentiary upgrade.